Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats
A diabetes drug shows heart benefits in obese patients but may raise blood pressure in lean people, highlighting the need for individualized treatment.
This preclinical study in hypertensive rats reveals that tirzepatide, despite reducing cardiovascular events in obese patients, may paradoxically elevate blood pressure and induce cardiac hypertrophy in non-obese hypertensive contexts via central sympathetic activation through hypothalamic POMC neurons. This context-dependency has potential clinical safety implications for tirzepatide use in non-obese/non-diabetic hypertensive patients.
What the study was
- Study design
- Controlled animal experiment (stroke-prone SHR rats, 4-week treatment, n=8-9/group)
- Population
- Stroke-prone spontaneously hypertensive rats (non-obese, non-diabetic hypertensive model)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Hypertension research
Why it surfaced
Counter-intuitive safety finding for tirzepatide in non-obese hypertension; context-dependent cardiovascular actions; capped at 5 (animal study only).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.